Pharsight

Qsymia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895057 VIVUS Escalating dosing regimen for effecting weight loss and treating obesity
Jun, 2028

(4 years from now)

US9011906 VIVUS Escalating dosing regimen for effecting weight loss and treating obesity
Jun, 2028

(4 years from now)

US9011905 VIVUS Low dose topiramate/phentermine composition and methods of use thereof
Jun, 2028

(4 years from now)

US8895058 VIVUS Low dose topiramate/phentermine composition and methods of use thereof
Jun, 2028

(4 years from now)

US8580298 VIVUS Low dose topiramate/phentermine composition and methods of use thereof
May, 2029

(5 years from now)

US8580299 VIVUS Escalating dosing regimen for effecting weight loss and treating obesity
Jun, 2029

(5 years from now)

Qsymia is owned by Vivus.

Qsymia contains Phentermine Hydrochloride; Topiramate.

Qsymia has a total of 6 drug patents out of which 0 drug patents have expired.

Qsymia was authorised for market use on 17 July, 2012.

Qsymia is available in capsule, extended release;oral dosage forms.

Qsymia can be used as use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight.

The generics of Qsymia are possible to be released after 14 June, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jun 24, 2025

Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient

Market Authorisation Date: 17 July, 2012

Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of QSYMIA before it's drug patent expiration?
More Information on Dosage

QSYMIA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic